Home
Welcome Note
Committees
International Advisory Board
Confirmed List of Faculty
Guidelines for Speakers
FIGO Post Graduate Course
Preliminary Program
Gynecology
Perinatology
Reproductive Medicine
Timetable
Main Topics
Scientific Program Synopsis
Timetable
Poster Presentations
Group A Posters
Group B Posters
Poster Display Guidelines
Registration & Accommodation
Registration
Accommodation
Swissôtel The Bosphorus
Invitation letter
Congress Information
Before you travel...
General Information
CME
Learners Feedback Questionnaire
Partners
Turkish Agent
Italian Agent
About Istanbul
Sponsorship & Exhibition
Information
Sponsors
Exhibitors
2012 Sponsors
Previous Congresses
BCGIP Barcelona 2012
BCGIP Bangkok 2011
Contact Us
  Reproductive Medicine & ART
Print

Times
Thursday, May 30, 2013
HALL C
17:00-19:00
BCGIP (COGI) CONGRESS OPENING SESSION
Chairpersons: Victor Gomel, Canada; Moshe Hod, Israel; Oktay Kadayıfçı, Turkey; Zeev Shoham, Israel
Industry support to independent research, legal code and ethical aspects
Amir Lass, Israel
New frontiers in Prenatal Diagnosis: From ultrasound to noninvasive prenatal testing
Alfred Abuhamad, USA
Istanbul: The old and the new
Victor Gomel, Canada
19:00-20:00
WELCOME RECEPTION in the Exhibition Area
Times
Friday, May 31, 2013
HALL C
08:30-10:00
NEW TRENDS IN ART
Organized by & in collaboration with the Institut Universitari Dexeus
Capsule:
How can we maximize pregnancy success rate?
Chairpersons: Pedro Barri, Spain; Buenaventura Coroleu, Spain; Milton Leong, Hong Kong
08:30-09:15
Debate: Embryo evaluation
Classical: Basak Balaban, Turkey
Time-lapse systems: Montserrat Boada, Spain
09:15-10:00
Debate: Delayed transfer
Fresh transfer: Dominique De Ziegler, France
Delayed frozen-thawed transfer: Miguel Angel Checa, Spain
10:00-10:30
Coffee Break in the Exhibition Area
10:30-12:30
BASIC UNDERSTANDING OF THE LUTEAL SUPPORT (LPS) IN ART TREATMENT CYCLES
Capsule: Ovarian stimulation results in supraphysiological steroid concentrations along with low LH levels during the luteal phase, approximately 8-9 days after hCG administration. This results in decreased corpus luteum production of estrogen and progesterone, which is associated with decreased probability of successful implantation and ongoing pregnancy.The triggering of the final stages of ovulation using either hCG (5,000-10,00IU) or GnRH-a induce specific, yet different adverse consequences on the luteal phase that call for corrective measures.
The program developed below was built to raise the controversies on the subject, striving to reach a consensus regarding lutal support in ART cycles.
Chairpersons: Dominique De Ziegler, France; Zeev Shoham, Israel
10:30-10:50
Is there a dose-effect relationship in the endometrial effects of progesterone?
Dominique De Ziegler, France
10:50-11:10
Why do we need additional progesterone when endogenous levels are so high?
Pedro Barri, Spain
 
PANEL DISCUSSION
11:10-11:25
Should LPS be adjusted to the COS regime?
Milton Leong, Hong Kong
11:25-11:40
Luteal phase support in ovulation induction cycles
Salim Daya, Canada
11:40-11:55
Which formulation should we use?
Roy Homburg, Israel
11:55-12:10
Which is the optimal duration of LPS in pregnancy: Science vs. clinical practice
Zeev Shoham, Israel
12:10-12:25
Is there a place for IM progesterone supplementation?
Sherman Silber, USA
12:30-13:15
Lunch Break in the Exhibition Area
13:15-14:15
Plenary Symposium (Hall B)
FROM SCIENCE FICTION TO REALITY
Capsule: There are tens of thousands of women with absolute uterine factor infertility. Furthermore, societal and regulatory restrictions preclude surrogacy in many parts of the World. Uterus transplant has been vetted in numerous arenas and has emerged as a very reasonable alternative to surrogacy and a supplement to adoption. Although successful pregnancies have been reported in animal models, is the time nearing to consider clinical translation? There are several groups of patients, mostly those treated for cancer and those beyond the reproductive age who will benefit from such technology. Is it real? Nanocarrier-mediated transport and controlled release of substrates at the cancer tissue would be probably to treatment of choice for cancer patients. The current state of this technology.
Chairpersons: Jacque Donnez, Belgium; Antonio Pellicer, Spain (Invitation was initiated by the Turkish Society of Reproductive Medicine)
 
Uterus transplantation
Giuseppe Del Priore, USA
 
The production of sperm and egg from somatic stem cells
Gerald Schatten, USA
 
Regenerative therapy with stem cell either adult and embryonic
Oktay Kadayifci, Turkey
14:15-16:15
HOW DO WE CHOOSE THE TREATMENT?
Chairpersons: Dominique De Ziegler, France; Zeev Shoham, Israel; Sedat Kadanalı, Turkey
14:15-14:35
Luteal support in ART treatment cycles: Is there a place for new/old formulation?
Salim Daya, Canada
14:35-14:55
Latest results from IVF worldwide survey
Zeev Shoham, Israel
14:55-15:15
Luteal phase after GnRH agonist ovulation triggering
Seang Lin Tan, Canada
 
PANEL DISCUSSION
15:15-15:25
Is there a risk involved in additional or high dose progesterone during the luteal phase or early pregnancy?
Dominique De Ziegler, France
15:25-15:35
Is there a role for gonadotropin releasing hormone (GnRH)-agonists as a luteal supplement in GnRH- agonist and antagonist stimulated cycles?
Pedro Barri, Spain
15:35-15:45
Active management of the luteal phase
Baris Ata, Turkey
15:45-15:55
Should hCG be added to all supplemented protocols?
Gedis Grudzinskas, UK
15:55-16:05
Is there a need for additional estrogen supplementation?
Ariel Weissman, Israel
16:05-16:15 Q & A
16:15-16:45
Coffee Break in the Exhibition Area
16:45-18:45
BREAST CANCER, CHEMOTHERAPY AND FERTILITY PRESERVATION
Capsule: Does it justify the efforts?
Chairperson: Pedro Barri, Spain; Uzi Beller, Israel; Attila Vereczkey, Hungary
 
Set the stage: Should fertility preservation be offered for social reasons?
Sherman Silber, USA
 
Ovarian tissue preservation in cancer patients
Dror Meirow, Israel
 
Banking cryopreserved ovarian cortical chips: default mode for all young women undergoing ovarian surgery?
Gedis Grudzinskas, UK
  Non-invasive imaging from Implantation through Birth by Combined High Resolution MRI and PET
Gerald Schatten, USA
Saturday, June 1, 2013
HALL C
08:30-10:00
INFERTILITY TREATMENT: HOW TO IMPROVE OUR PERFORMANCE
Capsule: The most commune diseases involved in infertility, How can we beat it?
Chairpersons: Cem Demirel, Turkey; Gerald Schatten, USA
08:30-09:00
The modern approach to PCOS: can we beat this syndrome
Roy Homburg, Israel
09:00-09:30
Embryo transfer: Tips for success
Bülent Tıraş, Turkey
09:30-10:00
Debate: Should embryo transfer always be performed under ultrasound guidance?
Yes: Salim Daya, Canada
No: Sherman Silber, USA
10:00-10:30
Coffee Break in the Exhibition Area
10:30-12:30
ADVANCED PATERNAL AGE & REPRODUCTION
Organized by & in collaboration with the Israeli Society of Reproductive Medicine
Capsule: Delaying childbirth has become a trend and is common in developed countries, reflecting increased life expectancy and the changing role of women in society. As couples' ages increase, so do the risks of reproductive problems. The negative effect of a woman's age on fertility has been well documented .However, ICSI procedure can easily circumvent the natural decline in sperm quality with age.
Chairperson: Martha Dirnfeld, Israel; Victor Gomel, Canada; Roy Homburg, Israel
10:30-11:10
Debate: Should male's age be limited in ART treatments?
Pro: Gedis Grudzinskas, UK
Con: Ilan Calderon, Israel
11:10-11:40
OHSS: a syndrome related to the past
Antonio Pellicer, Spain
Invitation was initiated by the Turkish Society of Reproductive Medicine
11:40-12:30
Meet the expert – can we tailor for the best stimulation protocol?
Capsule: Individual methods of stimulation is becoming the treatment of choice. What are the options for such a treatment?
Moderator: Sherman Silber, USA; Ariel Weissman, Israel
 

Panel Experts:
Hulisi Bulent Zeyneloglu, Turkey
Ariel Zosmer , UK
Daniel Seidman, Israel
Kuldeep Jain, India

Panel Topics:
Gonadotropins: the difference between the various components?
Do we still need LH? If it is now available to all, shall we use it?
After 10 years of r-gonadotropins? Does it justify the price?
Agonist vs. antagonist: is the debate over?
If the endometrium lining is 7 mm on day 2 – how will you manage?
38 y-o with AMH less than 1 and AFC 3/3 – how will you stimulate?
What is the role of DHEA in the stimulation protocol?
Can you prevent P rise by choosing particular protocol?

12:30-13:15
Lunch Break in the Exhibition Area
13:15-14:15
Plenary Symposium (Hall B)
Critical evaluation of Prediction and Prevention of Preeclampsia

Chairpersons: Riza Madazli, Turkey; Francesc Figueras, Spain

Is there a role of uterine Doppler screening
Elisa Llurba, Spain

Risk stratification of hypertensive pregnancy disorders
Stefan Verlohren, Germany

Critical evaluation: Is prediction of preeclampsia possible?
Francesc Figueras, Spain

Critical evaluation: The use of low molecular weight heparin as prophylactic therapy in women at high risk for PET
Jacob Bar, Israel
14:15-16:15
HOW TO CHOOSE THE BEST WAY TO HANDLE PREGNANCY AFTER CURED GYNECOLOGICAL CANCERS
Capsule: Following the improvement of vitrification methods, ertility preservation is the new immerging field giving hope to thousands of patients.
Chairperson: Vesna Stepanic, Croatia; Uzi Beller, Israel
14:15-14:45
How to treat the gynecological cancer itself (how aggressive the treatment could and should be to spare the woman's fertility)
Uzi Beller, Israel
14:45-15:15
How much can the cervix take with respect to pregnancy?
Achim Schneider, Germany
AGONIST TRIGGER: WHAT IS THE BEST APPROACH?
Capsule: GnRH agonist triggering eliminates early onset of OHSS. GnRHa-triggered cycle with a "freeze-all" policy would completely eliminate the risk of OHSS. However, this concept demands not only access to efficient crypreservation and endometrial priming programs for transfer of frozen embryos, but also radical changes of mind in patients and clinicians.
Chairperson: Ariel Weissman, Israel; Roy Homburg, Israel
15:15-16:15
Debate: Agonist trigger: what is the best approach?
GnRH triggering by fresh transfer:
Martha Dirnfeld, Israel
GnRHa-triggering followed by cryopreservation
Shahar Kol, Israel
16:15-16:30
Coffee Break in the Exhibition Area
16:30-18:00
NEW ADVANCES IN PGS
Capsule: Comprehensive chromosome analysis using microarrays is standardizing the genetic analysis of embryos for PGS, providing strong evidence of significant improvements in ART. Newer advances in genetic testing, such as Next Generation Sequencing, may further improve results. However, the biopsy methods used have not yet been agreed upon, with Europe moving towards PB analysis and the Americas toward blastocyst analysis, while day 3 biopsy may still be saved if coupled with vitrification on day 5.
Chairpersons: Ahmet Yesilyurt, Turkey; Andreas Schmutzler, Germany; Anupama Gupta, India
16:30-17:00
PGS using microarray and next generation sequencing analysis
Ahmet Yesilyurt, Turkey
17:00-18:00
Debate: how to improve ART efficacy?
Every embryo should be biopsies for a CGH or SNP and every oocyte should undergo cumulus cell analysis
Andreas Schmutzler, Germany
Are there alternatives to PGS for human embryo selection?
Samir Hamamah, France

Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 10/03/2013 Created by     WebStudio.co.il